Journal of Oncology Pharmacy Practice最新文献_第10页

Pharmacotherapeutic monitoring of tyrosine kinase inhibitors use in patients with chronic myeloid leukaemia: An integrative model proposal. 慢性髓性白血病患者使用酪氨酸激酶抑制剂的药物治疗监测：一个综合模型建议。

IF 0.9 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2026-03-02 DOI: 10.1177/10781552261423064

Gustavo Catarina Galdino, Joana Aparecida Rodrigues Pais, Victória Mattozo Rover, Marina Raijche Mattozo Rover

{"title":"Pharmacotherapeutic monitoring of tyrosine kinase inhibitors use in patients with chronic myeloid leukaemia: An integrative model proposal.","authors":"Gustavo Catarina Galdino, Joana Aparecida Rodrigues Pais, Victória Mattozo Rover, Marina Raijche Mattozo Rover","doi":"10.1177/10781552261423064","DOIUrl":"https://doi.org/10.1177/10781552261423064","url":null,"abstract":"IntroductionThe advent of tyrosine kinase inhibitors (TKI) has revolutionised the treatment of chronic myeloid leukaemia (CML). Nevertheless, no specific tools are currently available to support follow-up and guarantee the adequate management of safety, adherence, and effectiveness altogether of TKI-based regimens. This study aimed to introduce a monitoring instrument tailored to patients undergoing TKI therapy for CML.Data SourceA structured instrument proposal was developed after conducting an integrative review. The instrument was then evaluated by clinicians and laboratory professionals with expertise in onco-haematology, who assessed clarity, objectivity, practicality, and clinical relevance using a five-point Likert scale.Data SummaryThe model comprised three protocols designed to evaluate adherence, safety, and effectiveness of TKI therapy. During evaluation of the instrument, all assessed parameters achieved mean scores ≥ 3.0. By aligning with international guidelines, the instrument consolidates essential monitoring parameters, thereby enhancing clinical decision-making and supporting patient-centred care in CML.ConclusionInstruments of this nature are rare and represent an important challenge for healthcare teams managing CML patients. Considering that adherence and safety are critical determinants of therapeutic success, structured tools such as this have the potential to facilitate improved outcomes.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261423064"},"PeriodicalIF":0.9,"publicationDate":"2026-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147326289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Response to letter to the editor: A novel decision tree for performing risk assessments of biologics in a health-system setting. 致编辑的回复：在卫生系统环境中进行生物制剂风险评估的一种新的决策树。

IF 0.9 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2026-03-01 Epub Date: 2025-12-09 DOI: 10.1177/10781552251399542

Zoe Ngo, Scott Mayeda, Stacey Yu, Mark Danek, Austin Wang, Elyse A MacDonald, Ee Vonn Yong, Janjri Desai

引用次数: 0

Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: An integrative review. 免疫检查点抑制剂在治疗癌症和既往自身免疫性疾病患者中的应用：一项综合综述

IF 0.9 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2026-03-01 Epub Date: 2023-05-10 DOI: 10.1177/10781552231171881

Julia de Almeida Santos Freitas, Maria Teresita Bendicho, Aníbal de Freitas Santos Júnior

{"title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: An integrative review.","authors":"Julia de Almeida Santos Freitas, Maria Teresita Bendicho, Aníbal de Freitas Santos Júnior","doi":"10.1177/10781552231171881","DOIUrl":"10.1177/10781552231171881","url":null,"abstract":"IntroductionCheckpoint inhibitors (PCI) have reached an important place in the pharmaceutical market in the treatment of various types of cancer. However, due to immune-related adverse events (IRAE) to the treatment, patients with preexisting autoimmune diseases (PAD) are excluded from clinical studies, leading to a large gap in knowledge on this topic. This study aims to discuss the use of PCI in the patients with cancer and PAD by an integrative review.MethodsFor this integrative review we carried out research from 2013 to 2022 using database platforms for observational studies reporting data from safety and efficacy of PCI in patients with cancer and PAD.ResultsThe search resulted in 161 articles and after applying the exclusion criteria, 15 clinical studies that adopted a retrospective observational design were selected and analyzed. The age range of patients was 54-71 years, with 19-68% male. The proportion of patients clinically active or receiving immunosuppressants who were initiated on PCI ranged from 0% to 57% and 14% to 73%, respectively. The mean reported follow-up time ranged from 8.0 to 16.8 months. The occurrence of an outbreak or the new IRAE had an average of 32.6%.ConclusionIRAE are frequent in patients who use PCI and have cancer and PAD, carrying discontinuation of therapy. However, the multidisciplinary team needs to be aligned to manage these situations in the best way.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"329-336"},"PeriodicalIF":0.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9444191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The NHS SACT capacity crisis: Challenges and solutions. NHS SACT能力危机：挑战和解决方案。

IF 0.9 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2026-03-01 Epub Date: 2023-06-27 DOI: 10.1177/10781552231185050

Vikash Dodhia, Joanne Parkes, Aruni Ghose, Wendy Ng

引用次数: 0

Subcutaneous immune checkpoint inhibitors: A new era in oncology care. 皮下免疫检查点抑制剂：肿瘤治疗的新时代。

IF 0.9 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2026-03-01 Epub Date: 2025-10-27 DOI: 10.1177/10781552251390472

Casey L Keller, Ryan M Schuller, Saeed K Alzghari

引用次数: 0

Immune checkpoint inhibition in advanced colorectal cancer with inherited and acquired microsatellite instability: Current state and future directions. 具有遗传和获得性微卫星不稳定性的晚期结直肠癌免疫检查点抑制：现状和未来方向。

IF 0.9 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2026-03-01 Epub Date: 2023-05-29 DOI: 10.1177/10781552231178293

Constantin A Dasanu, Mohammed Alani, Shaghayegh Habibi, Ion Codreanu

{"title":"Immune checkpoint inhibition in advanced colorectal cancer with inherited and acquired microsatellite instability: Current state and future directions.","authors":"Constantin A Dasanu, Mohammed Alani, Shaghayegh Habibi, Ion Codreanu","doi":"10.1177/10781552231178293","DOIUrl":"10.1177/10781552231178293","url":null,"abstract":"ObjectiveThis paper reviews comprehensively the most relevant data on single-agent and combination therapies for advanced colorectal cancer with inherited and acquired microsatellite instability (MSI).Data SourcesWe performed a systematic search on PubMed and MEDLINE articles published from inception to December 2022. We have also searched independent websites including U.S. Food and Drug Administration and ClinicalTrials.gov.Data SummaryPerforming microsatellite stability testing, tumor mutational burden (TMB), and germline mutation analysis could identify patients with metastatic colorectal cancer that benefit from immune checkpoint inhibitor (ICI) therapy. Single-agent pembrolizumab has proven superiority over traditional chemotherapy in these patients. The nivolumab-ipilimumab is the only combination ICI therapy approved in this space. Recently, the anti-PD-1 antibody dostarlimab was granted Food and Drug Administration approval in refractory tissue-agnostic advanced solid cancers with deficient mismatch repair (dMMR). ICIs are also being studied in the adjuvant/neoadjuvant setting in colon cancer patients with dMMR. Newer agents are being scrutinized in this space as well. More solid data on biomarkers predicting responses in patients with MSI-high or TMB-H to various therapies are needed. Given its both clinical and financial toxicity, it is imperative to determine the optimal duration of ICI therapy in individual patients.ConclusionsOverall, the outlook in advanced colorectal cancer patients with MSI appears optimistic as new and efficacious ICI drugs and combinations are being added to the existing therapeutic armamentarium.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"349-357"},"PeriodicalIF":0.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9526544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

ISOPP International Symposium 2026 Abstracts. ISOPP国际研讨会2026摘要。

IF 0.9 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2026-03-01 Epub Date: 2026-03-20 DOI: 10.1177/10781552261417891

引用次数: 0

Case of nivolumab-induced delayed adrenal insufficiency during the treatment of renal cell carcinoma. 肾细胞癌治疗中尼伏单抗致迟发性肾上腺功能不全1例。

IF 0.9 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2026-03-01 Epub Date: 2023-03-29 DOI: 10.1177/10781552231163294

Ryo Yonezawa, Eriko Takata, Shiho Yamadera, Tomiko Sunaga

引用次数: 0

Oncology pharmacy practice in Nepal: Integration, challenges, and policy directions. 尼泊尔肿瘤药学实践：整合、挑战和政策方向。

IF 0.9 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2026-03-01 Epub Date: 2025-10-17 DOI: 10.1177/10781552251385482

Ajaya Acharya, Nabin Pathak, Sweta Shrestha, Santusta Adhikari, Sanjeev Sharma Kattel, Mandip Pokharel, Ramesh Sharma Poudel, Sunil Shrestha

引用次数: 0

Central line-associated Rhizobium radiobacter bloodstream infection in two allogeneic hematopoietic cell transplant recipients. 两例异基因造血细胞移植受者中央线相关放射根瘤菌血流感染。

IF 0.9 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2026-03-01 Epub Date: 2023-03-14 DOI: 10.1177/10781552231161826

Rachel E Hartman, Craig W Freyer, Vasilios Athans, Shannon R McCurdy, Noelle V Frey

{"title":"Central line-associated Rhizobium radiobacter bloodstream infection in two allogeneic hematopoietic cell transplant recipients.","authors":"Rachel E Hartman, Craig W Freyer, Vasilios Athans, Shannon R McCurdy, Noelle V Frey","doi":"10.1177/10781552231161826","DOIUrl":"10.1177/10781552231161826","url":null,"abstract":"IntroductionRhizobium radiobacter is a gram-negative, opportunistic phytopathogen that rarely causes human infections. We report two cases of Rhizobium radiobacter central line-associated bloodstream infection (CLABSI) in allogeneic hematopoietic cell transplantation (alloHCT) recipients. We review previous reports and common microbiological characteristics associated with this organism.Case reportsTwo adult males developed R. radiobacter CLABSIs at day +81 and day +77 post-alloHCT. Patient one was asymptomatic on presentation while patient two was febrile. One patient had a polymicrobial infection, which has not been previously described. The presence of high-level ceftazidime resistance in both patients suggests third-generation cephalosporin resistance may be more common than previously recognized.Management and outcomeFor both patients, microbiologic clearance was achieved through peripherally inserted central catheter removal and initiation of intravenous cefepime. Antibiotic therapy was narrowed to oral levofloxacin for a total 14-day course from the time of first negative blood culture. There has been no subsequent recurrence of R. radiobacter infection at 12 and 5 months of follow-up for patients one and two, respectively.DiscussionThese two cases add to the scant literature characterizing R. radiobacter infection following alloHCT. Immunosuppressive agents for graft-versus-host disease prophylaxis may have predisposed these patients to R. radiobacter infection. Our reports, and previously reported cases, suggest R. radiobacter exhibits low virulence, mild symptom burden, and does not confer a high mortality risk. In the alloHCT setting, further accumulation of cases is needed to aid in understanding clinical features and characteristics of R. radiobacter infection.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"383-387"},"PeriodicalIF":0.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9465835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0